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ABSTRACT
Breast cancer is the most commonly diagnosed cancer in women in the United States
and is the leading cause of cancer-related death among women worldwide. Certain
demographics, such as racial/ethnic, age, and gender groups, are underrepresented in breast
cancer studies. This lack of representation results in issues with creating genetic tests, as
variants associated with those groups are not being detected. Furthermore, these
underrepresented demographics are receiving a worse prognosis than those that are
overrepresented in research. This study aimed to understand how informed the understudied
racial/ethnic, gender, and age populations are regarding breast cancer and genetic testing
compared to populations that have been abundantly studied, and the factors affecting the
decision to receive genetic testing between gender groups. After distributing a survey to
students at the University of Central Florida, the study found that females answered the
knowledge-based questions more accurately than males; however, no significant differences
were found between age or ethnicity groups. This is likely due to the sample consisting of
university students who are more knowledgeable than the general population. The study found
a negative correlation between gender and the influence of individual health concerns on
receiving genetic testing and how often a breast self-exam is performed. A difference was also
found between gender, age, and ethnic groups on having performed a breast self-exam.
Further investigations should sample from a general population or other university populations
for comparison. Also, increased education on breast cancer risks, performing a breast selfexam, and receiving genetic testing would be beneficial for early detection of breast cancer.
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INTRODUCTION
The most commonly diagnosed cancer in American women is breast cancer, and it is the
leading cause of cancer-related death among women worldwide, but early detection and
increased awareness have contributed to the declining breast cancer-related death rate
(National Breast Cancer Foundation, Inc., 2020). When breast cancer is detected early in its
development, the prognosis may be better than if it were detected at a later stage when
symptoms would appear; moreover, it is typically not necessary for treatment to be aggressive
when the cancer is caught early, limiting the significant side effects and negative impact on the
quality of life of the patient (Fredricksson & Fredholm, 2017). In this way, a variety of treatment
options may be available, and these treatment options will be more effective. Increased
awareness and knowledge about breast cancer results in detection of breast cancer at a lower
stage (Kantelhardt et al., 2015).
Hereditary Breast Cancer Risks
Inheriting certain genetic mutations from a parent is the cause of approximately 5-10%
of breast cancer occurrences, with mutations in breast cancer gene 1 (BRCA1) or breast cancer
gene 2 (BRCA2) being the most common, accounting for approximately 3% of breast cancers
and 10% of ovarian cancers (American Cancer Society, 2019a; Centers for Disease Control and
Prevention [CDC], 2020b). The BRCA1 and BRCA2 genes normally protect the genome from
damage during DNA replication (American Cancer Society, 2019a). BRCA1 initiates the G2/M
and S-phase checkpoints and DNA repair during the replication process, and both BRCA1 and
1

BRCA2 function in homologous recombination (Roy et al., 2011). When mutations of these
genes occur, they are unable to protect the genome from any replication errors, and cells
become oncogenic.
When mutated, other genes that may increase the risk of breast cancer, including the
ataxia telangiectasia mutated (ATM), partner and localizer of BRCA2 (PALB2), Checkpoint Kinase
2 (CHEK2), Phosphatase and Tensin Homolog (PTEN), and tumor protein 53 (TP53) genes, as
listed by the American Cancer Society (2019a). Each of these genes is normally involved in the
cell cycle and DNA repair. ATM repairs damaged DNA or initiates apoptosis of the cell. PALB2 is
responsible for making proteins that interact with those made by the BRCA2 gene. CHEK2 aids
in repairing DNA. PTEN helps to regulate the growth of the cell. TP53 inhibits the growth of cells
that contain damaged DNA (American Cancer Society, 2019a). When these genes are unable to
perform their role due to genetic mutation, there is an increase in the risk of breast cancer or
syndromes, like Li Fraumeni syndrome, hereditary diffuse gastric cancer, or Cowden syndrome
(American Cancer Society, 2019a), associated with their inability to properly function.
Other factors that increase the risk of breast cancer include having a family history of
breast cancer, previously having breast cancer, race or ethnicity (e.g., Ashkenazi Jewish, African
American, or non-Hispanic white), being born female, aging, having breast tissue that is dense
with glandular and fibrous tissue, being diagnosed with certain benign breast conditions,
among others (American Cancer Society, 2019a). Some factors that reduce the risk of breast

2

cancer include limiting alcohol consumption, maintaining a healthy weight, exercising, and
breastfeeding (Mayo Clinic, 2021).
Breast Cancer Diagnosis and Treatment
According to the American Cancer Society (2018b), one in every eight women in the
United States (US) and one in 833 men, will develop breast cancer at some point in their
lifetime. Early detection, as well as increased public awareness of signs, prevention, and
treatment, have contributed to the declining rate of death caused by breast cancer. When
breast cancer is detected early, before symptoms appear, the patient’s prognosis is better and
the treatment is more effective than if the breast cancer was detected later in its development
(National Breast Cancer Foundation, Inc., 2020).
Breast cancer treatment options typically include surgery, radiation, chemotherapy,
hormone therapy, and targeted drug therapy to specifically target cancer-causing cell changes,
depending on which of the three clinical subtypes of breast cancer is present: hormone
receptor positive, triple-negative breast cancer (TNBC), or human epidermal growth factor
receptor 2 (HER2) positive breast cancer (American Cancer Society, 2021; National Cancer
Institute [NCI], 2021a).
Breast Cancer Research Advancements
The American Cancer Society (2019c) notes that current breast cancer research, is
focused on how lifestyle, habits, and inherited genes affect the risk of breast cancer. Studies
3

continue examine the effects of diet and exercise. A study by Klement et al. (2020) researched
the impact of a ketogenic diet during radiotherapy and found that the diet is feasible to reduce
body weight and fat mass, since obesity and low muscle mass are associated with a worse
prognosis for breast cancer patients. Some studies, like Gorelick et al. (2020) have been
determining the best use of genetic testing for mutations by studying how common genetic
variations may impact breast cancer risk, and how these small changes in the gene may have a
large impact when combined.
Other research mentioned by the American Cancer Society (2019c) is focused on
studying possible medications, including estrogen-blocking medications (tamoxifen and
raloxifene) and aromatase inhibitors (exemestane and anastrozole), and the immunotherapy
drug Atezolizumab studied by Schmid et al (2018). Atezolizumab was recently approved by the
FDA to treat patients with metastatic TNBC, as it is a Programmed Cell Death Ligand 1 (PD-L1)
inhibitor. The Programmed Cell Death Protein 1 (PD-1) checkpoint protein on T cells binds to
the protein PD-L1 on normal and cancer cells and prevents the T cell from attacking it. The PDL1 inhibitor prevents this binding so the cancer cells can be recognized by the T cells to be
attacked (American Cancer Society, 2019b).
Because 60-80% of breast cancer cells express androgen receptors (Kensler et al., 2019),
androgen receptor inhibitors are also being studied in clinical trials. Non-hormonal options that
are already available to treat other medical ailments, such as metformin, ruxolitinib, and
bexarotene, are beginning to be evaluated in clinical trials (American Cancer Society, 2019c).
4

Additionally, the National Cancer Institute (2021b) reported that a new imaging test
may be able to determine whether or not estrogen receptors in the patient’s tumors are active
and responding to estrogen, which is facilitating the cancer growth. Doctors can use this
information to come up with the best treatment plan for the patient.
Genetic Counseling and Testing for Breast Cancer
Genetic testing has become an invaluable tool in preventing the development of cancer
and creating treatment plans, especially for breast cancer, as it is able to test for specific
genetic mutations in a patient. The discovery of the BRCA1 and BRCA2 genes, in 1994 and 1995
(Wooster et al., 1994, 1995) respectively, altered the understanding and treatment of
hereditary breast and ovarian cancers to ultimately develop more opportunities for women to
undergo early detection screenings, like mammograms and MRIs, for prevention purposes
(Murthy & Muggia, 2019). These genetic testing processes detect potential mutations in the
BRCA genes, along with other genetic predispositions, that may increase the risk of developing
breast cancer and would provide patient-specific information for healthcare workers to refer to
when creating prevention or treatment plans with their patients.
Genetic counseling provides patients with a risk assessment of how they may be
affected by genetic conditions, and a genetic counselor will help determine if genetic testing is
necessary (CDC, 2019). Genetic counselors may also be able to answer questions regarding the
patient’s insurance coverage for genetic testing, especially for BRCA1 and BRCA2 variant
testing, as well as understanding the test results.
5

Age Disparities
It is generally encouraged for postmenopausal women to undergo genetic testing, along
with performing self-examinations, to assess their individual risk of developing breast cancer;
however, because only 7-10% of women diagnosed with breast cancer are under the age of 40
(Rossi, Mazzara, & Pagani, 2019), the age-specific issues these younger women face are not well
understood (Schaffar et al., 2019). Due to this relatively low incidence rate, there is not as much
emphasis on screening for breast cancer, like undergoing a mammogram or receiving genetic
testing, as there is for older age groups. As a result, this younger age group tends to be
diagnosed at a later and more advanced stage of breast cancer: 47% of breast cancer in young
women is diagnosed in an early stage, compared to 68% of older women (Cancer.Net, 2021).
Thus, young women are more likely to receive a more severe prognosis than their older
counterparts and to develop tumors with unfavorable characteristics (Radecka & Litwiniuk,
2016). This means that women below the age of 40 who have been diagnosed with an
advanced stage of breast cancer are likely to receive more aggressive and diverse treatment
options that can worsen the patient’s quality of life (Fredricksson & Fredholm, 2017). According
to Partridge et al., women 40 years old or younger are 30% more likely to die from breast
cancer than women over the age of 40.
Younger women are more likely to develop more aggressive breast cancer, like HER2positive or triple-negative breast cancers, than older women, who are more likely to develop
the less aggressive estrogen receptor-positive or progesterone receptor-positive breast cancers
6

(Helwick, 2021). These aggressive breast cancers that younger women tend to be diagnosed
with are more likely to spread beyond the breast and recur. This means more aggressive
treatment options are necessary to prevent recurrence. According to Rossi, Mazzara, and
Pagani (2019), women in this age group may be negatively impacted psychologically in regard
to family planning, returning to the workforce, and self-esteem. Young women diagnosed with
breast cancer may experience body image problems associated with mastectomy,
reconstructive surgeries, hair loss, and premature menopause, which causes hot flashes, weight
gain, and reduced sexual drive (Moriarty, 2020).
Gender Disparities
Even though male carriers of the BRCA 1 and 2 mutations are at a higher risk of
developing breast and prostate cancers than men who are not carriers, men account for 1% of
the breast cancer diagnoses in the United States, (CDC, 2020a). This discrepancy is because
most breast cancers begin in the ducts or glands of the breast, and these are not typically
functional in men (American Cancer Society, 2018a). Those who are diagnosed with male breast
cancer not only have to be concerned about the cancer, but also the social stigma surrounding
it: breast cancer is perceived to be a woman’s disease and its femininization in treatment
(Midding et al., (2018). One social stigmatization that men reported in a study by Midding et al.
(2018), was being prohibited from rehabilitation programs designed for female patients
because men are the minority of breast cancer patients, and these programs are designed with
women in mind. As a result of the stigmatization of breast cancer, men are more reluctant to
7

undergo genetic testing (Daly, 2009), and the majority of those who do get tested for these
mutations or risk factors do so for the benefit of their family, especially daughters (Hesse-Biber
& An, 2017). Additionally, according to the American Cancer Society (2018b), research on
breast cancer often focuses more on breast cancer in women than in men, resulting in
insufficient information on male breast cancer for both men and healthcare professionals to
refer to in order to provide quality treatment.
Previous mentions of “female” and “male” in this paper referred to cisgender
individuals: those who continue to identify as the sex assigned to them at birth. Due to
hormone replacement therapy or medical transition types and stages, transgender persons may
either increase or decrease their risk of breast cancer depending on how far into the transition
process they are (Quinn et al., 2015). Maglione et al. (2014) studied case reports of transgender
female (male-to-female) patients, and they concluded that there was an increase in the risk of
breast cancer due to the high doses of exogenous estrogen. These estrogen doses cause
development of breast tissue that is histologically similar to that of cisgender females and
suggests that screening for breast cancer in transgender female individuals should be done if
there are additional risk factors. A study conducted by Fehl et al. (2019) on breast cancer
among the transgender population found that transgender male (female-to-male) patients have
a lower rate of age-specific breast cancer in comparison to cisgender females as a result of
testosterone therapy and if a mastectomy had been performed. It should be noted that there is
a lack of information on breast cancer in transgender women, and any information that does
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exist is conflicting. The risk of breast cancer among female-to-male individuals is comparable to
that of biological males, and the risk for male-to-female individuals is comparable to that of
biological female persons (Quinn et al., 2015).
Racial and Ethnic Disparities
Despite the increase in genetic testing and genetic counseling as a whole, there are
racial and ethnic disparities that persist. Studies on breast cancer, and specifically the BRCA
genes, have been based on non-Hispanic white individuals, creating a deficiency of
representation in the data of African American, Hispanic, and Asian American populations in
these studies; therefore, there is a shortage of information from those populations, as different
racial or ethnic populations may carry different variants of a gene (National Cancer Institute,
2020). This is evidenced by the recommendation on risk assessment by the US Preventative
Services Task Force (2019), in which there is an expressed need for data on more racial and
ethnic groups in order to expand the database and make it more inclusive.
A recent study by Hoskins et al. (2021) suggested that the Oncotype DX Breast
Recurrence Score test used for women in early-stage breast cancer to help make treatment
decisions is less accurate for Black women than non-Hispanic white women. The test is
intended to measure how aggressive the breast cancer in a woman by looking at a group of
genes in the patient’s tumor and giving a score between 0-100 based on its activity level to
determine the risk of the cancer recurring and the patient’s risk of dying of the breast cancer.
Scores below 10 are considered low risk, 11-25 is considered intermediate risk, and 26 and
9

above is considered high risk. Individuals who have a high-risk score will receive chemotherapy
and hormone therapy after surgery, but those with low or intermediate scores only receive the
hormone therapy after surgery. The test by Hoskins et al. (2021) was developed using
information primarily from non-Hispanic white patients and very little information from Black
women due to the lack of participation from the latter population in the development of the
Oncotype DX Breast Recurrence Score test. Black women scored higher on the Oncotype DX
Breast Recurrence Score test than non-Hispanic white women, even after risk models had been
adjusted for age, the characteristics of the tumor, and treatment. This indicates that Black
women may biologically develop more aggressive tumors, and the information for the
development of the test that was provided primarily by non-Hispanic white women is
insufficient for testing on Black women. Additionally, the recurrence score did not provide as
much prognostic accuracy about Black women as non-Hispanic white women, as they were
more likely to die of breast cancer in all three risk categories. The authors suggest this is not a
valid test for Black women and may need to be calibrated differently when a Black patient is
being tested (Hoskins et al., 2021). This study highlights the need for more ethnic diversity in
research and the development of genetic tests.
Additionally, a study done by Cragun et al. (2017) found that Black and Hispanic
populations reported a lack of awareness of breast cancer resources, and a lack of utilization of
those resources. This study also noted that more research needs to be done on the racial
disparities associated with genetic testing and genetic counseling.
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Ashkenazi Jewish women have a 1 in 40 risk of having one of the three founder
mutations of the BRCA1 and BRCA2 genes; however, genetic screening for mutations is not
standard practice for a healthy Ashkenazi Jewish woman without a family history of breast
cancer, since BRCA-mutation screening has relied on family history (Metcalfe et al., 2015). This
means that these women will not be identified as a carrier for the mutation until after being
diagnosed with breast cancer. A study by Hadar et al. (2018) found that identifying a BRCA
mutation before a diagnosis of breast cancer correlated to a diagnosis of an early stage of
breast cancer.
In order to obtain a diverse sample for this study, the survey was distributed to the
student population at the University of Central Florida (UCF), as UCF possesses a large and
diverse student population of over 70,000 students. The known demographics of the survey
target population of UCF students consist of 46.3% Non-Hispanic White, 27.5% Hispanic or
Latino, 6.5% Asian or Pacific Islander, and 10.3% Black or African American students; 40,174
(55.8%) female students and 31,764 (44.2%) male students; and 78% under the age of 25, with
24.4 years old being the average age (University of Central Florida, 2020). Furthermore, the UCF
population consists of 6000 undergraduate and 400 graduate Jewish students, 14% of the UCF
student population, making it the third largest Jewish student population outside of Israel (Hillel
International, 2020).
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METHODS
Population and Sample Size
This research was conducted through a questionnaire (see Appendix), and composed of
demographic questions, family health background questions, and breast cancer-related
questions that have been formulated based on published research with similar aims.
The sample size necessary to achieve a power of 0.80 and an effect size of 0.15 for an a
priori power analysis was determined for each demographic variable. Using G*Power (Faul et
al., 2009), the minimum sample size needed for this research was determined to be 152
participants as the demographic variable requiring the largest sample size, ethnicity, required
152 participants, and would be an adequate sample size for each variable.
Survey
Approval for the study was obtained by the Institutional Review Board (IRB) before the
recruitment process began. Recruitment of participants was done with a posted recruitment
flyer and a recruitment flyer distributed via email, social media, and text messaging. The emails
were forwarded to students through UCF Webcourses and by UCF-affiliated persons and
organizations that were willing to distribute the survey. Personal identifying information was
not collected, and all participants remained anonymous. The survey could be accessed via a
provided hyperlink or a QR code that, once scanned, redirected the participant to the survey.
The questionnaire was administered to participants in one session of Qualtrics Research Suite,
12

an online software available to UCF students to create and distribute surveys, and consisted of
23 questions: 5 demographic questions, 3 family health background questions, and 15
awareness-based questions. Questions asked in the survey were to test and evaluate the extent
to which subpopulations of UCF students are knowledgeable about breast cancer and genetic
testing for predispositions to breast cancer. The survey was available for UCF students to
participate for about 2 months. Due to the varying types of data collected, multiple statistical
analyses were used: a Kruskal-Wallis test or Mann-Whitney U test to evaluate how well the
respondents scored on the knowledge-based questions, and a Spearman’s correlation to
evaluate the Likert scale questions.
Participants
To distribute the survey to UCF students, 664 emails were sent out to UCF professors
and UCF-affiliated organizations to forward the survey to their classes, posted multiple times on
various social media platforms, sent via text message, and via a posted recruitment flyer. The
study obtained a total of 197 participants. Responses from participants under eighteen years
old and participants who did not give consent were not obtained. All participants are UCF
students, and those who indicated otherwise were not included. Incomplete responses were
not included. The final sample size of the study was 166 participants.
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Statistical Analysis
A Kruskal-Wallis test or Mann-Whitney U test, depending on the amount of groupings
being analyzed, were used to analyze how well the respondents answered the knowledgebased questions regarding breast cancer and genetic testing. Analysis was done according to
gender, age, ethnicity, and Ashkenazi Jewish ethnicity. A Spearman’s correlation was used to
evaluate the extent to which the respondents agreed with the statements of the Likert scale.
Analysis was done according to gender, age, and ethnicity. Additionally, a Spearman’s
correlation was also used to analyze influential factors, including family planning, health
concerns, and social stigmatizations, that affect the decision to receive genetic testing, by
gender. IBM SPSS Statistics version 27 is the tool used for the statistical data analysis of results
of the survey.
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RESULTS
Demographic Data of Survey Participants

Figure 1. Demographic Data of Survey Participants. The (A) gender, (B) age, (C) race/ethnicity, (D) Ashkenazi Jewish
ethnicity of the participants is displayed.

Figure 1A refers to the gender makeup of the survey participants: of the 166 study
participants, 138 (83.1%) indicated that they were female, 26 (15.7%) indicated that they were
male, and 2 (1.2%) identified as nonbinary. Figure 1B details the age distribution of the survey
participants. The results of the survey found that 90 (54.2%) survey participants indicated that
they were 18-21 years old, 62 (37.3%) indicated they were 22-26 years old, 7 (4.2%) were 27-30
years old, 4 (2.4%) were 31-35 years old, 2 (1.2%) were 36-40 years old, and one participant
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(0.6%) was over 40 years old. For statistical analysis purposes, participants who indicated they
were 27-30, 31-35, 36-40, or over 40 were combined into one group: 27 and over. Figure 1C
shows that the race/ethnicity of the survey participants was 18 (10.9%) Asian or Pacific Islander,
13 (7.8%) Black or African American, 39 (23.5%) Hispanic or Latino, and 86 (51.8%) non-Hispanic
white. Additionally, 10 (6.0%) participants indicated “other,” meaning that they are a race that
was not listed as a specific choice in the survey. Figure 1D indicates the percentage of
participants who are Ashkenazi Jewish, in which 6.0% of the survey participants indicated that
they are Ashkenazi Jewish, which is lower than UCF population’s 14% provided by Hillel
International (2020).
Approximately 36.8% of the survey respondents indicated that they have a family
history of breast cancer, with 6.6% indicating that they have or a first-degree family member
has been diagnosed with breast cancer. 17.5% of survey participants have been encouraged to
receive genetic testing to detect breast cancer, with 16.3% indicating that have already
received or will seek out genetic testing to evaluate their risk of breast cancer. Furthermore,
31.9% of the survey participants indicated that they have never performed a breast self-exam,
and 12.1% of participants indicated that they do not know how to perform one.
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General Breast Cancer and Genetic Testing Knowledge
Table 1
Results of the Knowledge-Based Questions of All Survey Participants
Question

Percentage of Persons who Answered Correctly

Men cannot develop breast cancer.

94.0

Genetic testing for breast cancer mutations
is only necessary if there is a family history
of breast cancer.

87.4

Testing Positive for breast cancer mutation
means I will develop breast cancer.

89.8

Testing negative for breast cancer mutation
means I will not develop breast cancer.

95.8

Genetic mutations may increase the risk of
developing breast cancer.

95.8

Health insurance may cover genetic testing
for breast cancer.

76.5

Average Percent Correct

89.9

Statistical analysis of the data distribution found the data to be non-parametric. The average score of the
participants was 89.9%.
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Table 2
Results of the Knowledge-Based Questions by Gender

Question

Percentage of Persons who Answered Correctly
(Percent of Total Respondents)
Female
Male
Nonbinarya
(83.1%)
(15.7%)
(1.2%)

Men cannot develop breast cancer.

96.4

80.8

100.0

Genetic testing for breast cancer mutations
is only necessary if there is a family history
of breast cancer.

85.5

96.2

100.0

Testing Positive for breast cancer mutation
means I will develop breast cancer.

89.9

84.6

50.0

Testing negative for breast cancer mutation
means I will not develop breast cancer.

96.4

96.2

50.0

Genetic mutations may increase the risk of
developing breast cancer.

97.8

84.6

100.0

Health insurance may cover genetic testing
for breast cancer.

76.8

80.8

0.0

Average Percent Correct

90.5*

87.2

66.7

a

The nonbinary group was excluded from the statistical analysis due to its low sample size. The accuracy of the
female participants was significantly higher than the male participants (Mann-Whitney U test, U=1398, p=0.045).
*p value < 0.05.

18

Figure 2. Results of the Knowledge-Based Questions by Gender. The average percent correct scored by the female
group was 90.5%; meanwhile, the average percent correct scored by the male group was 87.2%. The accuracy of
the female participants was significantly higher than the male participants (Mann-Whitney U test, U=1398,
p=0.045).
*p value < 0.05.

Statistical analysis showed that the data has a non-parametric distribution. The
“nonbinary” group was excluded in the statistical analysis because n=2 for this group, which
was not large enough for statistical analysis, so only two gender groups were analyzed. Thus,
the Mann-Whitney U test was the appropriate test to determine significance exists between
gender and the knowledge of breast cancer and genetic testing. With a mean rank for the
female group of 85.37 and 67.27 for the male group, it can be concluded that the accuracy of
answers of the knowledge-based questions was significantly higher in the female group than in
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the male group (Mann-Whitney U test, U=1398, p=0.045, where ‘U’ is the test statistic, and ‘p’
is the significance).

Table 3
Results of the Knowledge-Based Questions by Age

Question

Percentage of Persons who Answered Correctly
(Percent of Total Respondents)
18-21
22-26
27 and over
(54.2%)
(37.4%)
(8.4%)

Men cannot develop breast cancer.

93.3

96.8

85.7

Genetic testing for breast cancer mutations
is only necessary if there is a family history
of breast cancer.

86.7

90.3

78.6

Testing Positive for breast cancer mutation
means I will develop breast cancer.

85.6

93.6

100.0

Testing negative for breast cancer mutation
means I will not develop breast cancer.

93.3

100.0

92.9

Genetic mutations may increase the risk of
developing breast cancer.

94.4

98.4

92.9

Health insurance may cover genetic testing
for breast cancer.

78.9

71.0

85.7

Average Percent Correct

88.7

91.7

89.3

No statistically significant differences were found (Kruskal-Wallis test, H(2)=1.187, p=0.552).
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Figure 3. Results of the Knowledge-Based Questions by Age. The average percent correct for the 18-21 age group
was 88.7%, 91.7% for the 22-26 age group, and 89.3% for those 27 years old and older. No statistically significant
differences were found (Kruskal-Wallis test, H(2)=1.187, p=0.552).

The data obtained from the results of the general breast cancer knowledge questions by
age group was found to be non-parametric; thus, the Kruskal-Wallis test was used in place of
the one-way ANOVA. Because of the low number of respondents who indicated they are in the
age groups “27-30,” “31-35,” “36-40,” and “Over 40,” these age groups have been combined
into one group, denoted as “27 and older” in order to adequately proceed with the statistical
analysis. Difference in the medians of the knowledge between the age groups was not
statistically significant (Kruskal-Wallis test, H(2)=1.187, p=0.552).
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Table 4
Results of the Knowledge-Based Questions by Ethnicity

Question

Percentage of Persons who Answered Correctly
(Percent of Total Respondents)
Asian or
Black or
Hispanic
NonOther
Pacific
African
or Latino
Hispanic
Islander
American
White
(10.9%)
(7.8%)
(23.5%)
(51.8%)
(6.0%)

Men cannot develop breast cancer.

88.9

100.0

92.3

95.4

90.0

Genetic testing for breast cancer
mutations is only necessary if there
is a family history of breast cancer.

100.0

92.3

89.7

84.9

70.0

Testing Positive for breast cancer
mutation means I will develop
breast cancer.

83.3

76.9

89.7

91.9

100.0

Testing negative for breast cancer
mutation means I will not develop
breast cancer.

94.4

100.0

94.9

96.5

90.0

Genetic mutations may increase
the risk of developing breast
cancer.

100.0

100.0

89.7

97.7

90.0

Health insurance may cover genetic
testing for breast cancer.

72.2

84.6

74.4

76.7

80.0

Average Percent Correct

89.8

92.3

88.5

90.5

86.7

No statistically significant differences were found (Kruskal-Wallis test, H(4)=1.547, p=0.818).
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Figure 4. Results of the Knowledge-Based Questions by Ethnicity. No statistically significant differences were found
(Kruskal-Wallis test, H(4)=1.547, p=0.818). The average percent correct for the Asian or Pacific Islander group was
89.8%, 92.3% for the Black or African American group, 88.5% for the Hispanic or Latino group, 90.5% for the NonHispanic White group, and 86.7% for the participants who indicated “Other.”

Statistical analysis of the distribution of the results of the general breast cancer
knowledge questions when grouped by ethnicity was found to be non-parametric. There was
no statistically significant difference found in the medians of the knowledge between the
different ethnicity groups (Kruskal-Wallis test, H(4)=1.547, p=0.818).
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Table 5
Results of the Knowledge-Based Questions by Ashkenazi Jewish Ethnicity

Question

Percentage of Persons who Answered Correctly
(Percent of Total Respondents)
Ashkenazi Jewish
Not Ashkenazi Jewish
(6.0%)
(94.0%)

Men cannot develop breast cancer.

100.0

93.6

Genetic testing for breast cancer mutations
is only necessary if there is a family history
of breast cancer.

80.0

87.8

Testing Positive for breast cancer mutation
means I will develop breast cancer.

100.0

89.1

Testing negative for breast cancer mutation
means I will not develop breast cancer.

100.0

95.5

Genetic mutations may increase the risk of
developing breast cancer.

100.0

95.5

Health insurance may cover genetic testing
for breast cancer.

70.0

76.9

Average Percent Correct

91.7

89.7

No statistically significant differences were found (Mann-Whitney U test, U=732, p=0.715). The average percent
correct was 91.7% for the Ashkenazi Jewish participants, and 89.7% for the non-Ashkenazi Jewish participants.
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Figure 5. Results of the Knowledge-Based Questions by Ashkenazi Jewish Ethnicity. No statistically significant
differences were found (Mann-Whitney U test, U=732, p=0.715).

Statistical analysis of the distribution of the results of the general breast cancer
knowledge questions when grouped by Ashkenazi Jewish ethnicity was found to be nonparametric. No statistically significant difference was found in knowledge between the
Ashkenazi Jewish and not Ashkenazi Jewish groups (Mann-Whitney U test, U=732, p=0.715).
Awareness of Breast Cancer Resources
The Likert Scale response data obtained from question 22 was converted to a numerical
system: “Prefer not to answer” =0, “Strongly Disagree” =1, “Somewhat Disagree” =2, “Neutral”
=3, “Somewhat Agree” =4, and “Strongly Agree” =5. The Likert Scale data obtained from
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question 24 was also converted to a numerical system: “Prefer not to answer” =0, “I do not
know how to perform a breast self-exam” =1, “Never” =2, “Occasionally” =3, “Weekly” =4,
“Monthly” =5, and “Yearly” =6. Statistical analysis of the data distribution of this question found
the data to be non-parametric; thus, a Spearman’s correlation, in which ‘r’ defines the
correlation coefficient and ‘p’ defines the significance, was the appropriate test for analyzing
correlations in the Likert scale data between age group or ethnicity and responses.
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Figure 6. Knowledge of Genetic Testing and Genetic Counseling. Frequency of responses for question 22, part a, "I
am informed about genetic testing and genetic counseling” by (A) gender, (B) age group, and (C) ethnicity. No
statistically significant differences were found in Figure 6A (Spearman’s correlation, r=0.031, p=0.689), Figure 6B
(Spearman’s correlation, r=0.026, p=0.736), nor in Figure 6C (Spearman’s correlation, r=0.122, p=0.119).
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Figure 6 shows the responses for question 22, part a, “I am informed about genetic
testing and genetic counseling.” No correlation was found between gender and Likert Scale
response given (Spearman’s correlation, r=0.031, p=0.689) in Figure 6A, age group and
response in Figure 6B (Spearman’s correlation, r=0.026, p=0.736), and ethnicity and response in
Figure 6C (Spearman’s correlation, r=0.122, p=0.119).
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Figure 7. Knowledge of Breast Cancer Resources. Frequency of responses for question 22, part b, "I am aware of
the breast cancer resources available to me" by (A) gender, (B) age group, and (C) ethnicity. In Figure 7A, there was
a significant negative correlation between gender and response. (Spearman’s correlation, r=-0.173, p=0.027). The
data of the male participants was more skewed to the left, indicating disagreement with the statement, while the
data of the female participants was more evenly distributed across the Likert scores. No statistically significant
difference was found in Figure 7B (Spearman’s correlation, r=0.125, p=0.111) nor in Figure 7C (Spearman’s
correlation, r=0.095, p=0.223).
*p value < 0.05.
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Figure 7 shows the results of question 22, part b, “I am aware of the breast cancer
resources available to me.” A statistically significant negative correlation was found between
gender and the Likert scale response given (Spearman’s correlation, r=-0.173, p=0.027). Figure
7A shows that the male data were skewed right, more towards the disagreeing responses, and
the female response distribution was more consistent across the responses. No correlation was
found between age group and the Likert scale response given (Spearman’s correlation, r=0.125,
p=0.111), nor between ethnicity and response (Spearman’s correlation, r=0.095, p=0.223).
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Figure 8. Likelihood of Genetic Testing. Frequency of responses for question 22, part c, "I am likely to receive
genetic testing to evaluate my risk of developing breast cancer" by (A) gender, (B) age group, and (C) ethnicity. No
statistically significant differences were found in Figure 8A (Spearman’s correlation, r=-0.148, p=0.059), Figure 8B
(Spearman’s correlation, r=-0.061, p=0.434), nor in Figure 8C (Spearman’s correlation, r=-0.012, p=0.879).
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Figure 8 shows there was no correlation was found between Likert Scale response for
question 22, part c, “I am likely to receive genetic testing to evaluate my risk of developing
breast cancer” and gender (Spearman’s correlation, r=-0.148, p=0.059), although the p value
was close to indicating a significant difference had been found. Additionally, no correlation was
found between response and age group (Spearman’s correlation, r=-0.061, p=0.434), nor
between response and ethnicity (Spearman’s correlation, r=-0.012, p=0.879).
Influential Decision Factors for Genetic Testing by Gender
Statistical analysis found the data of question 22, according to gender, to be nonparametric; thus, a Spearman’s correlation was the appropriate statistical test to analyze the
data. Because n=2 for the “nonbinary” group, this group was not included in the statistical
analysis.
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Figure 9. Influence of Family Planning on Receiving Genetic Testing. Frequency of responses for question 22, part d,
"Family planning would influence my decision to receive genetic testing." No statistically significant differences
were found. (Spearman’s correlation, r=-0.019, p=0.809).

With the results shown in Figure 9, no correlation was found between gender and
question 22, part d, “Family planning would influence my decision to get genetic testing,”
(Spearman’s correlation, r=-0.019, p=0.809).
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Figure 10. Influence of Own Health Concerns on Receiving Genetic Testing. Frequency of responses for question
22, part e, "My decision to receive genetic testing is influenced by my own health concerns." The graph of the
female responses increased as the response agreed more with the statement. The graph of the male participants
showed an increase, until a peak at “Somewhat Agree” and then the graph decreased between “Somewhat Agree”
and “Strongly Agree.” (Spearman’s correlation, r=-0.270, p<0.01).
**p value < 0.01.

In Figure 10, significant negative correlation was found between gender and question
22, part e, “My decision to receive genetic testing is influenced by my own health concerns,”
(Spearman’s correlation, r=-0.270, p<0.01) at the 0.01 level in the 2-tailed test. The female
participants have an increasing trend across the data; meanwhile, the male participants also
have an increasing trend, but the responses then decrease between “Somewhat Agree” and
“Strongly Agree.”
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Figure 11. Influence of Social Pressure on Receiving Genetic Testing. Frequency of responses for question 22, part f,
"My decision to receive genetic testing is influenced by social pressure." No statistically significant differences
were found. (Spearman’s correlation, r= 0.137, p=0.08).

Using the results shown in Figure 11, no correlation was found between gender and
question 22, part f, “My decision to receive genetic testing is influenced by social pressure,”
(Spearman’s correlation, r= 0.137, p=0.08).
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Figure 12. Breast Self-Exam Ever Performed. Responses for question 23, “Have you ever performed a breast selfexam?” A statistically significant difference was found in Figure 12A between gender and question 23 (MannWhitney U test, U=584, p<0.05), in Figure 12B between age and question 23 (Kruskal-Wallis, H(2)=10.921,
p=0.004), and in Figure 12C between ethnicity and question 23 (Kruskal-Wallis test, H(4)=11.707, p=0.02).
*p value < 0.05
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The question “Have you ever performed a breast self-exam?” was analyzed in Figure 12.
A significant difference was found between the genders, in which the female group reported to
having performed a breast self-exam more than the male group (Figure 12A; Mann-Whitney U
test, U=584, p<0.05). A significant difference was also found between the 18-21 and 22-26 age
groups, where the 18-21 group reported to having performed a breast self-exam less than the
22-26 group (Figure 12B; Kruskal-Wallis, H(2)=10.921, p=0.004). In Figure 12C, the Non-Hispanic
White group reported performing a breast self-exam more than the Asian or Pacific Islander
group (Kruskal-Wallis test, H(4)=11.707, p=0.02).
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Figure 13. Breast Self-Exam Performance Regularity. Frequency of responses for question 24, “How often do you
perform a breast self-exam?” A statistically significant correlation was found for gender in Figure 13A (Spearman’s
correlation, r=-0.409, p<0.01), age in Figure 13B (Spearman’s correlation, r=0.285, p<0.01), and ethnicity in Figure
13C (Spearman’s correlation, r=0.167, p=0.032).
*p value < 0.05
**p value < 0.01
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The question “How often do you perform a breast self-exam?” was analyzed in Figure
13. Figure 13A shows that the males had a significant negative correlation to the females
(Spearman’s correlation, r=-0.409, p<0.01) at the 0.01 level in the two-tailed test. In Figure 13B,
a significant positive correlation was found between age and question 24 (Spearman’s
correlation, r=0.285, p<0.01) at the 0.01 level in the two-tailed test. Lastly, a significant positive
correlation was found between ethnicity and question 24, shown in Figure 13C (Spearman’s
correlation, r=0.167, p=0.032) at the 0.05 level in the two-tailed test.
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DISCUSSION
This study was done to understand the awareness of genetic predispositions to breast
cancer of understudied populations compared to abundantly studied populations, sampling
from the diverse UCF population. Compared to the 2020-2021 general UCF population makeup
(UCF, 2020), the survey received a higher number of female participants: 83.1% compared to
the expected 55.8%. A possible reason for this could be that male-identifying, nonbinary, or
transgender students may have felt discouraged from participating in the survey because of its
relation to breast cancer and that they may not have been the target population for the study.
A potential way to improve this in future studies would be to recruit from more fraternities or
to hang up fliers in more common areas around campus that the male population might be
more able to see.
Additionally, the racial/ethnic distribution the sample consisted of slightly more nonHispanic white and Asian or Pacific Islander students than the population, and less of the other
racial/ethnic populations.
There were also fewer individuals who indicated they are Ashkenazi Jewish, 6.0%, than
the expected 14.0%, as per Hillel International (2020). This problem may possibly be resolved in
future studies by distributing to more Jewish-based groups and organizations. When comparing
the knowledge between the Ashkenazi Jewish and non-Ashkenazi Jewish groups, no significant
difference was found. This further refutes the hypothesis that understudied populations are not
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as knowledgeable as abundantly studied populations, since those who are Ashkenazi Jewish- a
group that is abundantly studied in breast cancer research, is not more knowledgeable than
non-Ashkenazi Jewish individuals. However, this may be due to the sample consisting of
university students, who may be more knowledgeable than the general population on these
topics.
The UCF student population, as mentioned earlier, is over 70,000 students. Attempts
were made to reach the students through posting flyers on campus, social media posts, and
requests for distribution from professors and organizations affiliated with UCF. Despite these
efforts, it is highly unlikely that the survey was distributed to every UCF student, as the study
received only 197 responses. The low number of responses could be due to the timing of the
study, as it was sent out at the end of the spring semester and the beginning of the summer
semester, when students may not be as interested to partake in a study due to graduation, final
exams, getting settled for the new semester, or not even taking classes. Had the study been
sent out earlier in the semester, when students had already settled into a routine and would
have potentially had more time to be able to complete the survey, then the study may have
received more responses. The study may have also received more responses had the survey
been available for a longer period of time than the two months it had been available for, or
multiple distribution attempts of the survey may have been necessary.
For the knowledge-based questions, all survey participants answered the questions
more accurately than anticipated: the average percent correct of all of the participants was
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89.9% and that of the different groupings analyzed ranged between 81.2% to 92.3%, excluding
the “nonbinary” group, since there were only two survey participants who fell into this group. It
is worth noting that responses for question 19, “Health insurance may cover genetic testing for
breast cancer,” were typically lower than average in all groupings, with the average of all
participants for this question being 76.5% compared to averages between 87.4% and above for
the other questions. This may be due to lack of knowledge about insurance policies as a whole,
and what is covered under health insurance.
The statistical analysis of the knowledge-based questions found that the hypothesis that
understudied racial populations are not as informed of breast cancer resources and genetic
testing as those that have been abundantly studied is incorrect. These findings do not reflect
the findings of other studies, such as Cragun et al. (2017), that reported a lack of awareness of
resources among Black and Hispanic populations. A possible explanation for this is that the
survey participants were all university students, and thus may be more knowledgeable than the
general public regarding breast cancer resources. These findings highlighted the success of
education, as there are less racial disparities among this population.
The accuracy of answers of the knowledge-based questions was statistically significantly
higher in the female group than in the male group, and the hypothesis that men are not as
knowledgeable about breast cancer resources as women is correct. This difference could relate
to the results of the Likert scores, where the male participants indicated more that they felt
they were unaware of the breast cancer resources available to them.
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When analyzing the data by gender, a statistically significant negative correlation was
found in question 22, part b, “I am aware of the breast cancer resources available to me,” and
part e, “My decision to receive genetic testing is influenced by my own health concerns.” In
Figure 7A, the female responses were more distributed across the Likert scale; meanwhile, the
male responses were skewed right, indicating that they did not agree that they were aware of
the breast cancer resources available to them. In Figure 10, the graph of the female responses
increased as the response agreed more with the statement. The graph of the male participants
showed an increase, until a peak at “Somewhat Agree” and then the graph decreased between
“Somewhat Agree” and “Strongly Agree.” This change in the data could be due to the low
number of male participants in the study, and the results may be different if this study were
done again with a larger male sample. A possible explanation for these overall findings is that
breast cancer resources are becoming more widely available and not just directed towards
women, or that these populations are in similar stages of life- most under the age of 40 when
routine breast cancer screening is recommended- and that the statements posed by the survey
are just not applicable at this time. In the age of technology, where information on any topic is
readily available all the time, these populations have the resources available for if and when it
is needed, but these preparations may not be a concern at the moment, since breast cancer
screenings are not recommended until the age of 40 or if breast cancer symptoms appear,
despite the 36.8% of participants who indicated that they have a family history of breast
cancer. A possible solution to this would be to educate younger individuals on risk factors and
when they should receive genetic testing. Additionally, routine breast cancer screenings and
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risk assessments should become more encouraged for younger individuals, even if the chance
that breast cancer will be detected is low. This will both encourage younger individuals to begin
thinking about their risk of developing breast cancer, while also determining the individual risk
of developing breast cancer in the future or detecting breast cancer in its early stages.
There were no other statistically significant findings, which is not reflected by previous
research conducted on these topics, such as that of Daly, et al. (2009) regarding social
stigmatizations surrounding breast cancer for men and the study by Cragun et al. (2017) on
racial disparities in knowledge of breast cancer and genetic testing and available resources on
those topics. This could be due to the low number of male participants studied, or it could be
due to social changes that involve acceptance and an emphasis on getting help when needed.
Another reason could be that these men have not experienced any social stigmatizations that
would cause them to have an opinion on receiving genetic testing as a whole. Furthermore, the
lack of differences between ethnicities could be due to the sample consisting of university
students who are more knowledgeable about these topics than the general population and
more cognizant of their health and being healthier as a whole.
The study found that the respondents are not as knowledgeable performing a breast
self-exam, as 31.9% indicated that they have never performed a breast self-exam, and 12.1% of
participants indicated that they do not know how to perform one. For question 23, “Have you
ever performed a breast self-exam?,” a statistically significant difference was found between
genders, where the results showed that the female participants have performed a breast self44

exam while the male participants have not. A significant difference was also found based on
age, where the data indicated that the 22-26 age group has performed a breast self-exam more
than the 18-21 age group. Lastly, a significant difference was found between ethnicities. The
graph of the data showed that the non-Hispanic white group reported performing a breast selfexam more than the Asian or Pacific Islander group.
For question 24, “How often do you perform a breast self-exam?,” a significant
correlation was found between and gender. The male participants mostly indicated that they
have either never performed a breast self-exam or that they were unaware of how to perform
one. A significant correlation was also found between age groups, where the 18-21 age group
leaned more towards the less frequent side of the Likert scale, as they indicated more often
than the older groups that they either never performed a breast self-exam or they were
unaware of how to perform one. A significant correlation was also found between ethnicities.
The Asian or Pacific Islander and Black or African American groups performed a breast selfexam less frequently than the other ethnic groups (Figure 13C). These are the data from the
respondents of the survey, and do not necessarily reflect the views of the UCF population as a
whole. It is possible that the results could differ if the number of respondents were larger in
future studies.
Bringing awareness to the importance of performing a breast self-exam and providing
the resources necessary to learn how to perform one would be beneficial for early detection of
breast cancer. Since this study focused on UCF students, these findings can be shared with
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UCF’s Student Health Services to potentially incorporate breast examinations during routine
examinations or provide information on how to perform a breast self-exam directly to students.
Additionally, future studies should be done with samples from the general population, and with
an emphasis on the understudied populations, such as younger individuals, those who identify
as male or nonbinary, and ethnic groups other than the non-Hispanic white population. These
were groups that did not have a high representation in the data, so results of the data may
change if the representation of these groups is higher in a future study. Another shortcoming of
the study was that the survey did not ask about the socioeconomic status of the participants, so
this was not something that could be evaluated in the analysis to find any potential
correlations. Bringing more awareness of the availability of breast cancer resources and further
research into the disparities between understudied populations, early detection of breast
cancer can increase so the breast cancer-related death rate can continue to decrease.
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APPENDIX
QUESTIONNAIRE
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Q1 Are you a UCF student?

o Yes
o No
Display This Question:
If Are you a UCF student? = No

Q3 This survey is only for UCF students. Thank you for your time and interest.

Q4 Please indicate your age.

o Under 18
o 18-21
o 22-26
o 27-30
o 31-35
o 36-40
o Over 40
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Display This Question:
If Please indicate your age. = Under 18

Q5 You must be 18 years or older to complete this survey. Thank you for your time and
interest.

Skip To: End of Survey If You must be 18 years or older to complete this survey. Thank you for
your time and interest. Is Displayed

Q6 Please indicate your gender.

o Female
o Male
o Trans-female
o Trans-male
o Nonbinary
o Another gender
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Q7 Please indicate your ethnicity.

o Non-Hispanic White
o Black or African American
o Hispanic or Latino
o Asian or Pacific Islander
o Native American
o Other

Q8 Are you Ashkenazi Jewish?

o Yes, I am Ashkenazi Jewish
o No, I am not Ashkenazi Jewish

Q9 Do you have a family history of breast cancer?

o Yes
o No
o Prefer not to answer
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Q10 Have you or a first-degree family member been diagnosed with breast cancer?

o Yes
o No
o Prefer not to answer

Q11 Have you received or will you receive genetic testing to evaluate your risk of developing
breast cancer?

o Yes
o No
o Prefer not to answer
Q12 Please answer the following questions to the best of your ability.

Q13 Men cannot develop breast cancer.

o True
o False
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Q14 Genetic testing for breast cancer mutations is only necessary if there is a family history of
breast cancer.

o True
o False

Q16 Testing positive for a breast cancer mutation means I will develop breast cancer.

o True
o False

Q17 Testing negative for a breast cancer mutation means I will not develop breast cancer.

o True
o False
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Q18 Genetic mutations may increase the risk of developing breast cancer.

o True
o False
Q19 Health insurance may cover genetic testing for breast cancer.

o True
o False
Q20 I have been encouraged to receive genetic testing for breast cancer.

o True
o False
Q22 Please indicate the extent to which you agree or disagree with the following statements.
Strongly
Disagree

Somewhat
Disagree

Neutral

Somewhat
Agree

Strongly
Agree

Prefer
not to
answer

a.

I am
informed
about
genetic
testing and
genetic
counseling.

o

o

o

o

o

o

b.

I am aware
of the
breast
cancer

o

o

o

o

o

o
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resources
available
to me.
I am likely
to receive
genetic
testing to
evaluate
my risk of
developing
breast
cancer.

o

o

o

o

o

o

d.

Family
planning
would
influence
my
decision to
get genetic
testing.

o

o

o

o

o

o

e.

My
decision to
receive
genetic
testing is
influenced
by my own
health
concerns.

o

o

o

o

o

o

f.

My
decision to
receive
genetic
testing is
influenced
by social
pressure.

o

o

o

o

o

o

c.
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Q23 Have you ever performed a breast self-exam?

o Yes
o No
o I prefer not to answer

Q24 How often do you perform a breast self-exam?

o Never
o Occasionally
o Weekly
o Monthly
o Yearly
o I do not know how to perform a breast self-exam
o I prefer not to answer
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